Home › Urothelial (Transitional Cell) Carcinoma › Massachusetts › Boston
Urothelial (Transitional Cell) Carcinoma clinical trials in Boston, MA
11 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #7, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RecruitingPhase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
RecruitingObservational study
- Mass General Brigham, Boston
- Brigham and Women's Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
- Tufts Medical Center, Boston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
- Massachusetts General Hospital, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- Dana Farber Cancer Institute, Boston
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
RecruitingPhase 1
- Dana-Farber Cancer Institute, Boston
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
RecruitingPhase 3
- Research Site, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
RecruitingPhase 1
- Dana Farber Cancer Institute, Boston
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
RecruitingObservational study
- Dana-Farber Cancer Institute, Boston
Sacituzumab Govitecan Plus EV in Metastatic UC
RecruitingPhase 1/2
- Dana Farber Cancer Institute, Boston
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN23 studies
- New York City, NY22 studies
- Houston, TX19 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- San Antonio, TX11 studies
- Austin, TX10 studies
- Orange, CA10 studies
Other studies in Boston
- Breast Cancer112 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)85 studies
- Metastatic Cancer63 studies
- Colorectal Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.